Sangamo Therapeutics Announces Q1 2024 Financial Results and ...

Sangamo Therapeutics Announces Third Quarter 2024 Conference ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 ...

Sangamo Therapeutics Company Profile 2024 - PitchBook

As of 30-Jun-2024, Sangamo Therapeutics has a trailing 12-month revenue of $12.3M. ... Peer performance insights compare the company's ESG performance to the ...

Sangamo Therapeutics Inc.: Corporate Call and Q4 Update

13/03/2024 - Sangamo Therapeutics Inc.: Corporate Call and Q4 Update · Highly specific repression, with no impact to other Nav channels · Starting ...

News Releases | Investor Relations | Sangamo Therapeutics, Inc.

BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 1, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the ...

Sangamo Therapeutics is about to announce its earnings

Sangamo Therapeutics reveals figures for Q1 on May 9. 8 analysts are predicting losses of $0.214 per share as opposed to earnings of $0.130 ...

Sangamo Therapeutics on X: "We announced first quarter business ...

We announced first quarter business highlights and financial results including how we continue to progress our neurology-focused genomic ...

Sangamo Therapeutics (Nasdaq:SGMO) - Stock Price, News ...

New major risk - Revenue and earnings growth. Nov 13 ; Consensus revenue estimates fall by 17%. Nov 07 ; Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on ...

sangamo therapeutics reports recent business highlights and first ...

The increase of $2.0 million in revenues was primarily attributed to an increase of $1.0 million related to our collaboration agreement with ...

Fierce Biotech Layoff Tracker 2024

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking industry layoffs.

SGMO Sangamo Therapeutics, Inc. Stock Price & Overview

(SGMO) Q1 2024 Earnings Call Transcript · SA Transcripts ... Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results.

Fate Therapeutics Reports First Quarter 2024 Financial Results and ...

(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ( ...

FY2024 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical ...

Sangamo Therapeutics - Overview, News & Similar companies

Sangamo Therapeutics has recently released 2024 Q1 report with the following insight: SANGAMO has a strong neurology pipeline and scientific capabilities ...

News Releases | Investor Relations | Sangamo Therapeutics, Inc.

BRISBANE, Calif. --(BUSINESS WIRE)--May 4, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Consolidated net loss for the first quarter ended March 31, 2024 was $49.1 million, compared to a net income of $21.1 million, for the same ...

SEC Filings - Sangamo Therapeutics, Inc.

SEC Filings ; Nov 12, 2024, 10-Q · Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings.

AstraZeneca 25 April 2024 Q1 2024 results Very strong revenue and ...

At our Annual General Meeting we were pleased to announce a 7% increase in the annual dividend, and at our. Investor Day on 21 May 2024 we will ...

News Releases | Investor Relations | Sangamo Therapeutics, Inc.

RICHMOND, Calif. , April 4, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Sangamo is eligible to earn from Pfizer up to $220 million in milestone payments upon the achievement of certain regulatory and commercial ...

Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into ...

Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights ... Revenue: $0.5M for Q1 2024, significantly below estimates ...